RemeGen stock
688331.SSSHHRemeGen Co. Ltd. Class A, HealthcareISIN CNE100005B03
44Score 44 out of 100, Weak
Price and trend
45 / 100
Price history
+14% in one yearThe chart shows daily closes over 5 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 16% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 47).
The price is 36% below its 52-week high. Largest decline in 5 years: 76% (February 2023 to September 2024).
Chart figures for advanced users
- SMA 50$16.30
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$17.49
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)47
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$11.60
- The lowest closing price of the last twelve months.
- Resistance$22.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- RemeGen Co. Ltd. Class A belongs to the Biotechnology industry (China) and, with a market value of $8.26B, is number 45 of 296 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $1.14B (up 134.9%) and adjusted earnings per share of $1.22 (up 566.3%).
- MEQIRI Score 44 out of 100 (Weak): rank 477 of 714 in Healthcare, median 53.
Show more
- The P/E is 76.2 (Biotechnology median 46.6, own median of recent years 60.3).
- Our model puts fair value at $9.01, with the price 65% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 21.8% over the last 12 months, Biotechnology median 12.4%.Profitability 70
- More cash than debtCash $363.14M, financial debt $330.06M.Stability 72
Weaknesses
- DilutionShare count up 35% since 2020.Capital allocation 21
- Negative free cash flowFree cash flow −$21.56M over the last 12 months.Fundamentals 21
- Richly valuedP/E 76.2, Biotechnology median 46.6, own median 60.3.Valuation 22
Its standout strengths are stability and profitability, while fundamentals and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 43 to 44.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $6.01 and expensive above $18.02 (uncertainty very high, based on the price swings of the past year).
Valuation metrics
From earnings times the industry P/E (46.6) alone; there are no viable cash flows for the cash-flow model.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 89.3% on the prior year. Revenue has grown strongly since 2021, at around 23% per year. From 2021 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 81%, operating 4%, net 22%. From 2021 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 31 Mar 2027in 139 days
- Last reported
- 29 Oct 2026EPS reported $0.16
Analyst estimates
Analysts have raised their 2026 earnings estimate by 5.9% since 28 Oct 2026.
- Earnings per share
- $1.22+5.9%
- Revenue
- $1.14B+0.3%
- Earnings per share
- $0.20+3.6%
- Revenue
- $647.8M−2.7%
MEQIRI has stored the estimates since 28 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at RemeGen
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 44
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Praxis Precision MedicinesPRAX $9.67B42
- Alteogen196170.KQ $9.56B57
- Krystal BiotechKRYS $9.15B66
- Protagonist TherapeuticsPTGX $8.73B68
- Asymchem Laboratories (Tianjin)002821.SZ $8.26B64
- ALK-AbellóALK-B.CO $8.18B74
- CytokineticsCYTK $8.15B34
- 10x GenomicsTXG $8.12B43
ETFs that hold RemeGen
Held by 28 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI China A UCITS ETF36BZ | 0.08% | 0.40% | €1.79B |
| Xtrackers Harvest CSI A500 UCITS ETF 1DAH50 | 0.08% | 0.65% | €10.8M |
| iShares MSCI China UCITS ETFICGA | 0.02% | 0.28% | €2.22B |
Show 5 more
| Franklin FTSE China UCITS ETFFLXC | 0.01% | 0.19% | €1.3B |
| iShares MSCI EM Consumer Growth UCITS ETFCEMG | 0.01% | 0.60% | €31.52M |
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.01% | 0.30% | €134.65M |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.00% | 0.17% | €5.24B |
| iShares Core MSCI EM IMI UCITS ETFIS3N | 0.00% | 0.18% | €37.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CN¥6.6707)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.